Released on: January 7, 2008, 10:58 am

Press Release Author: GTCBIO

Industry: Pharmaceuticals

Press Release Summary: Jianhua Chao, Principal Scientist of Discovery Chemical
Research at Schering-Plough will give a presentation entitled "Potent, Orally Active
CXCR2-CXCR1 Antagonists as Anti-inflammatory Therapy" at GTCbio's 6th Cytokines and
Inflammation. (January 28-29, 2008, Orlando, Florida)

Press Release Body: FOR IMMEDIATE RELEASE
January 7, 2008

Schering Plough to Present at GTCbio's 6th Cytokines and Inflammation (January
28-29, 2008, Orlando, Florida)

Jianhua Chao, Principal Scientist of Discovery Chemical Research at Schering-Plough
will give a presentation entitled "Potent, Orally Active CXCR2-CXCR1 Antagonists as
Anti-inflammatory Therapy" at GTCbio's 6th Cytokines and Inflammation. (January
28-29, 2008, Orlando, Florida)

Dr. Jianhua Chao is a Principal Scientist of Discovery Chemical Research at
Schering-Plough Research Institute. She joined SPRI at the end of 2000 as a Senior
Scientist shortly after her completion of Ph.D. study. Over the past seven years,
she has been actively involved in a number of discovery research projects ranging
across allergy, pulmonary, inflammation, and CNS therapy areas. She has also played
a leadership role in a couple of Schering-Plough /Pharmacopeia collaboration
projects. In the CXCR2 antagonists program, Dr. Chao and her colleagues have
discovered and developed a novel series of receptor antagonists, one of which has
been selected as a clinical candidate and being progressed in phase II studies for
the treatment of chronic inflammatory disorders. She is an inventor / coinventor of
eighteen patents & patent applications, and an author / coauthor of five scientific
publications. Dr. Chao received her Ph.D. degree in Synthetic Organic Chemistry
from Florida State University under the direction of Professor Robert A. Holton.
Her graduate work focused on the total synthesis of complex natural product Taxol
and its 1-deoxy analog. Her strong interest is to apply synthetic capabilities into
probing biological targets, design and develop new medications for people and
society

The conference also features presentations from other leading organizations such as
Amgen, AstraZeneca, Biogen Idec, FDA, Genentech, Merck, NIH, Novo Nordisk, Pfizer,
Roche, and many more. The full agenda is available online at www.gtcbio.com.

GTCbio's 6th Cytokines and Inflammation conference will take place on January 28-29,
2008 at the Orlando Metropolitan Resort in Orlando, Florida and will cover Cytokines
Signaling and Regulation, Inflammation and Cancer, Technological Developments in
Cytokines Biology, Chemokines, and Targeting of Cytokine Receptors

For more information including a detailed agenda, exhibitor opportunities and
registration information visit http://gtcbio.com/userAgenda.aspx?id=115



ABOUT GTCbio

GTCbio organizes conferences specifically for the biomedical and biopharmaceutical
industries. Our goal is to facilitate the exchange of biopharmaceutical and
biomedical intelligence between industry leaders, academic and government
organizations, and the financial community.

GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company
founded in 2002.

Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, raniah@gtcbio.com








Web Site: http://

Contact Details: Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, raniah@gtcbio.com